NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Paratek Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.55 +0.04 (+1.14 %) (As of 01/28/2020 09:40 AM ET) Add Compare Today's Range$3.54Now: $3.55▼$3.5650-Day Range$2.95MA: $3.79▼$4.5052-Week Range$2.66Now: $3.55▼$7.39Volume7,498 shsAverage Volume993,750 shsMarket Capitalization$118.18 millionP/E RatioN/ADividend YieldN/ABeta1.82 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CUSIP89354M10 CIK1178711 Webhttp://www.paratekpharma.com/ Phone617-807-6600Debt Debt-to-Equity RatioN/A Current Ratio9.80 Quick Ratio9.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$17.12 million Price / Sales6.90 Cash FlowN/A Price / Cash FlowN/A Book Value$1.48 per share Price / Book2.40Profitability EPS (Most Recent Fiscal Year)($3.57) Net Income$-112,360,000.00 Net Margins-505.07% Return on Equity-5,327.73% Return on Assets-45.09%Miscellaneous Employees101 Outstanding Shares33,290,000Market Cap$118.18 million Next Earnings Date2/26/2020 (Estimated) OptionableOptionable Receive PRTK News and Ratings via Email Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PRTK Rates by TradingView Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions What is Paratek Pharmaceuticals' stock symbol? Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK." How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals Inc (NASDAQ:PRTK) posted its earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.06) by $0.06. The specialty pharmaceutical company earned $3.93 million during the quarter, compared to analyst estimates of $3.63 million. Paratek Pharmaceuticals had a negative return on equity of 5,327.73% and a negative net margin of 505.07%. View Paratek Pharmaceuticals' Earnings History. When is Paratek Pharmaceuticals' next earnings date? Paratek Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Paratek Pharmaceuticals. What price target have analysts set for PRTK? 7 equities research analysts have issued 12 month price targets for Paratek Pharmaceuticals' shares. Their forecasts range from $6.00 to $36.00. On average, they expect Paratek Pharmaceuticals' share price to reach $17.33 in the next twelve months. This suggests a possible upside of 388.3% from the stock's current price. View Analyst Price Targets for Paratek Pharmaceuticals. What is the consensus analysts' recommendation for Paratek Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Paratek Pharmaceuticals. What are Wall Street analysts saying about Paratek Pharmaceuticals stock? Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock: 1. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (1/15/2020) 2. HC Wainwright analysts commented, "We view the promotion of Dr. Loh as particularly well-deserved and quite likely to be broadly well-received by investors and other constituents. Affirm Buy." (6/26/2019) Has Paratek Pharmaceuticals been receiving favorable news coverage? Media headlines about PRTK stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Paratek Pharmaceuticals earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Paratek Pharmaceuticals. Are investors shorting Paratek Pharmaceuticals? Paratek Pharmaceuticals saw a decline in short interest in January. As of January 15th, there was short interest totalling 8,260,000 shares, a decline of 11.2% from the December 31st total of 9,300,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the days-to-cover ratio is presently 7.0 days. Approximately 29.9% of the shares of the stock are short sold. View Paratek Pharmaceuticals' Current Options Chain. Who are some of Paratek Pharmaceuticals' key competitors? Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Zogenix (ZGNX). What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), EXACT Sciences (EXAS), Exelixis (EXEL), Verastem (VSTM), Energy Transfer LP Unit (ET), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Omeros (OMER), Cara Therapeutics (CARA) and Dynavax Technologies (DVAX). Who are Paratek Pharmaceuticals' key executives? Paratek Pharmaceuticals' management team includes the folowing people: Mr. Michael F. Bigham, Chairman & CEO (Age 61)Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 60)Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 57)Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 52)Mr. Douglas W. Pagán, Consultant (Age 47) How do I buy shares of Paratek Pharmaceuticals? Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Paratek Pharmaceuticals' stock price today? One share of PRTK stock can currently be purchased for approximately $3.55. How big of a company is Paratek Pharmaceuticals? Paratek Pharmaceuticals has a market capitalization of $118.18 million and generates $17.12 million in revenue each year. The specialty pharmaceutical company earns $-112,360,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe.View Additional Information About Paratek Pharmaceuticals. What is Paratek Pharmaceuticals' official website? The official website for Paratek Pharmaceuticals is http://www.paratekpharma.com/. How can I contact Paratek Pharmaceuticals? Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected] MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 387 (Vote Outperform)Underperform Votes: 348 (Vote Underperform)Total Votes: 735MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/28/2020 by MarketBeat.com StaffFeatured Article: Portfolio Manager
